Tiziana Life Sciences PLC (LON:TILS)‘s stock had its “speculative buy” rating reiterated by stock analysts at Beaufort Securities in a report released on Thursday. They presently have a GBX 400 ($5.17) price target on the biotechnology company’s stock. Beaufort Securities’ target price points to a potential upside of 163.16% from the company’s current price.

Shares of Tiziana Life Sciences PLC (LON:TILS) traded down 0.33% during trading on Thursday, reaching GBX 152.00. 1,583 shares of the company’s stock traded hands. Tiziana Life Sciences PLC has a 52-week low of GBX 102.06 and a 52-week high of GBX 240.00. The company’s 50-day moving average is GBX 160.35 and its 200 day moving average is GBX 182.31. The company’s market cap is GBX 143.48 million.

COPYRIGHT VIOLATION NOTICE: This article was published by American Banking News and is owned by of American Banking News. If you are reading this article on another website, it was stolen and reposted in violation of international trademark and copyright laws. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/09/10/tiziana-life-sciences-plc-tils-receives-speculative-buy-rating-from-beaufort-securities.html.

About Tiziana Life Sciences PLC

Tiziana Life Sciences PLC is a clinical-stage biotechnology company. The Company is focused on targeted drugs to treat diseases in oncology and immunology, with a focus on metastatic cancers. Its products in clinical stage include Milciclib and Foralumab. Its products in pre-clinical stage include TZLS-101 and TZLS-214.

Receive News & Ratings for Tiziana Life Sciences PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tiziana Life Sciences PLC and related companies with MarketBeat.com's FREE daily email newsletter.